Gyre Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Contract with Customer, Liability of -$230.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2023-10-26
- Gyre Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-12-31 was $0.00.
- Gyre Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-09-30 was $0.00.
- Gyre Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2022-03-31 was -$230.00K.
- Gyre Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$230.00K.
- Gyre Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$1.75M.
- Gyre Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was -$13.02M, a 186.78% decline from fiscal 2019.
- Gyre Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2019 was $15.00M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $0.00 derived: sum of 3 quarters · filed 2023-10-26 | -$230.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | -$230.00K 10-Q · filed 2023-10-26 | -$853.00K derived: sum of 4 quarters · filed 2023-10-26 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$230.00K 10-Q · filed 2023-08-14 | -$853.00K derived: sum of 3 quarters · filed 2023-08-14 | -$2.04M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$230.00K 10-Q · filed 2023-05-15 | -$853.00K derived: sum of 2 quarters · filed 2023-05-15 | -$2.04M derived: sum of 3 quarters · filed 2023-05-15 | -$1.33M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$1.81M derived: sum of 2 quarters · filed 2023-03-30 | -$1.10M derived: sum of 3 quarters · filed 2023-03-30 | -$1.75M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$1.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$479.00K derived: sum of 2 quarters · filed 2022-11-14 | -$1.13M 10-Q · filed 2022-11-14 | $89.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $706.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $55.00K 10-Q · filed 2022-08-15 | $1.27M derived: sum of 3 quarters · filed 2022-08-15 | $1.71M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$651.00K 10-Q · filed 2022-05-09 | $568.00K derived: sum of 2 quarters · filed 2022-05-09 | $1.00M derived: sum of 3 quarters · filed 2022-05-09 | $1.33M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.65M derived: sum of 2 quarters · filed 2022-03-31 | $1.98M derived: sum of 3 quarters · filed 2022-03-31 | -$13.02M 10-K · filed 2022-03-31 |
| 2020-09-30 | $434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $764.00K derived: sum of 2 quarters · filed 2021-11-12 | -$14.24M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $330.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$14.67M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$15.00M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $15.00M 10-K · filed 2021-03-04 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | $0.00 derived: sum of 2 quarters · filed 2020-02-20 | $0.00 derived: sum of 3 quarters · filed 2020-02-20 | -$6.00K 10-K · filed 2020-02-20 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | -$6.00K 10-Q · filed 2019-11-07 | -$324.00K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$6.00K 10-Q · filed 2019-08-01 | -$324.00K derived: sum of 3 quarters · filed 2019-08-01 | -$642.00K derived: sum of 4 quarters · filed 2019-08-01 |
| 2018-03-31 | -$6.00K 10-Q · filed 2019-05-02 | -$324.00K derived: sum of 2 quarters · filed 2019-05-02 | -$642.00K derived: sum of 3 quarters · filed 2019-05-02 | |
| 2017-12-31 | -$318.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$636.00K derived: sum of 2 quarters · filed 2019-03-08 | -$118.00K 10-K · filed 2019-03-08 | |
| 2017-09-30 | -$318.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $200.00K 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $518.00K 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |